Logo image of CLGN

COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis

NASDAQ:CLGN - IL0004960188 - Common Stock

2.72 USD
+0.11 (+4.31%)
Last: 9/5/2025, 8:05:13 PM
Fundamental Rating

3

Overall CLGN gets a fundamental rating of 3 out of 10. We evaluated CLGN against 542 industry peers in the Biotechnology industry. While CLGN seems to be doing ok healthwise, there are quite some concerns on its profitability. CLGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLGN has reported negative net income.
In the past year CLGN has reported a negative cash flow from operations.
CLGN had negative earnings in 4 of the past 5 years.
In the past 5 years CLGN reported 4 times negative operating cash flow.
CLGN Yearly Net Income VS EBIT VS OCF VS FCFCLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

CLGN has a worse Return On Assets (-80.58%) than 67.90% of its industry peers.
Looking at the Return On Equity, with a value of -111.85%, CLGN is in line with its industry, outperforming 42.80% of the companies in the same industry.
Industry RankSector Rank
ROA -80.58%
ROE -111.85%
ROIC N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
CLGN Yearly ROA, ROE, ROICCLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

With a decent Gross Margin value of 48.71%, CLGN is doing good in the industry, outperforming 75.28% of the companies in the same industry.
CLGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLGN Yearly Profit, Operating, Gross MarginsCLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLGN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLGN has more shares outstanding
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLGN Yearly Shares OutstandingCLGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CLGN Yearly Total Debt VS Total AssetsCLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

CLGN has an Altman-Z score of -7.20. This is a bad value and indicates that CLGN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.20, CLGN is not doing good in the industry: 66.61% of the companies in the same industry are doing better.
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.2
ROIC/WACCN/A
WACC8.82%
CLGN Yearly LT Debt VS Equity VS FCFCLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 4.48 indicates that CLGN has no problem at all paying its short term obligations.
CLGN's Current ratio of 4.48 is in line compared to the rest of the industry. CLGN outperforms 49.82% of its industry peers.
CLGN has a Quick Ratio of 4.23. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.23, CLGN is in line with its industry, outperforming 49.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.48
Quick Ratio 4.23
CLGN Yearly Current Assets VS Current LiabilitesCLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.91% over the past year.
The Revenue for CLGN has decreased by -95.30% in the past year. This is quite bad
Measured over the past years, CLGN shows a very negative growth in Revenue. The Revenue has been decreasing by -25.99% on average per year.
EPS 1Y (TTM)16.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.32%
Revenue 1Y (TTM)-95.3%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%-28.11%

3.2 Future

The Earnings Per Share is expected to grow by 22.83% on average over the next years. This is a very strong growth
CLGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.05% yearly.
EPS Next Y78.34%
EPS Next 2Y41.67%
EPS Next 3Y22.83%
EPS Next 5YN/A
Revenue Next Year546.26%
Revenue Next 2Y231.28%
Revenue Next 3Y73.05%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLGN Yearly Revenue VS EstimatesCLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
CLGN Yearly EPS VS EstimatesCLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLGN. In the last year negative earnings were reported.
CLGN is valuated quite expensively with a Price/Forward Earnings ratio of 266.67.
Based on the Price/Forward Earnings ratio, CLGN is valued cheaply inside the industry as 86.53% of the companies are valued more expensively.
CLGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.69.
Industry RankSector Rank
PE N/A
Fwd PE 266.67
CLGN Price Earnings VS Forward Price EarningsCLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLGN Per share dataCLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CLGN's earnings are expected to grow with 22.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.67%
EPS Next 3Y22.83%

More info and screens

0

5. Dividend

5.1 Amount

CLGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (9/5/2025, 8:05:13 PM)

2.72

+0.11 (+4.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners13.06%
Inst Owner Change15.66%
Ins Owners29.91%
Ins Owner ChangeN/A
Market Cap34.60M
Analysts82.86
Price Target12.24 (350%)
Short Float %0.71%
Short Ratio1.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-119.92%
Min EPS beat(2)-218.63%
Max EPS beat(2)-21.21%
EPS beat(4)0
Avg EPS beat(4)-76.23%
Min EPS beat(4)-218.63%
Max EPS beat(4)-21.21%
EPS beat(8)1
Avg EPS beat(8)296.42%
EPS beat(12)1
Avg EPS beat(12)161.42%
EPS beat(16)1
Avg EPS beat(16)99.24%
Revenue beat(2)0
Avg Revenue beat(2)-43.31%
Min Revenue beat(2)-62.78%
Max Revenue beat(2)-23.83%
Revenue beat(4)0
Avg Revenue beat(4)-56.16%
Min Revenue beat(4)-99.06%
Max Revenue beat(4)-23.83%
Revenue beat(8)1
Avg Revenue beat(8)-51.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-366.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-181.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 266.67
P/S 14
P/FCF N/A
P/OCF N/A
P/B 2.79
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)0.01
Fwd EY0.38%
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.19
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.58%
ROE -111.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.71%
FCFM N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.92%
Cap/Sales 16.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.48
Quick Ratio 4.23
Altman-Z -7.2
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.32%
EPS Next Y78.34%
EPS Next 2Y41.67%
EPS Next 3Y22.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-95.3%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%-28.11%
Revenue Next Year546.26%
Revenue Next 2Y231.28%
Revenue Next 3Y73.05%
Revenue Next 5YN/A
EBIT growth 1Y-75.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.87%
OCF growth 3YN/A
OCF growth 5YN/A